Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.62 |
| ▸ | ABL1 | P00519 | 3/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.39 |
| ▸ | STK4 | Q13043 | 1/20 | 0.39 |
| ▸ | STK3 | Q13188 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600571 | 0.91 | MAP4K1 (0.62) | MAP4K1ABL1LRRK2JAK2JAK3 | |
| SCHEMBL2600565 | 0.90 | MAP4K1 (0.61) | MAP4K1ABL1LRRK2JAK2JAK3 | |
| SCHEMBL2600576 | 0.88 | MAP4K1 (0.58) | MAP4K1ABL1LRRK2JAK2JAK3 | |
| SCHEMBL2600535 | 0.84 | ABL1 (0.72) | MAP4K1ABL1LRRK2JAK2JAK3 | |
| SCHEMBL2600528 | 0.84 | ABL1 (0.60) | MAP4K1ABL1LRRK2JAK2JAK3 | |
| SCHEMBL2111075 | 0.82 | MAP4K1 (0.52) | MAP4K1ABL1LRRK2JAK2JAK3 | |
| SCHEMBL2600619 | 0.82 | MAP4K1 (0.52) | MAP4K1ABL1LRRK2JAK2JAK3 | |
| SCHEMBL2600553 | 0.81 | MAP4K1 (0.71) | MAP4K1ABL1LRRK2JAK2JAK3 | |
| SCHEMBL2111079 | 0.81 | MAP4K1 (0.53) | MAP4K1ABL1LRRK2CHRNA7KIT | |
| SCHEMBL2600588 | 0.80 | MAP4K1 (0.71) | MAP4K1ABL1LRRK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | PDXK, MAP3K4, PDPK1 | MAP4K1 16/4885ABL1 862/4885LRRK2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.